When squamous cell lung cancer has spread beyond the lungs to other parts of the body, patients and their families face complex treatment decisions. Understanding the available options—from standard chemotherapy to innovative therapies being tested in clinical trials—can help patients work with their healthcare teams to find the approach that best fits their individual situation and goals.

Facing Advanced Lung Cancer: What Treatment Aims to Achieve

Metastatic squamous cell lung cancer, also known as stage 4 or advanced squamous cell carcinoma, refers to a situation where cancer cells that started in the lung’s squamous cells have traveled to other parts of the body. These thin, flat cells normally line the airways like the lining of a pipe, but when they become abnormal and begin to multiply uncontrollably, they can eventually spread through the bloodstream or lymph system to the liver, bones, brain, or other organs.^[1][7]

The main goals of treatment for metastatic squamous cell lung cancer are different from those for earlier-stage disease. Because the cancer has spread throughout the body, doctors typically focus on controlling symptoms, slowing down the cancer’s growth, and improving the patient’s quality of life. While cure is rarely possible when cancer has metastasized, many patients can live longer and feel better with appropriate treatment. The specific treatment plan depends on several factors including how widely the cancer has spread, the patient’s overall health and strength, the presence of specific biological markers in the tumor cells, and the patient’s personal preferences and treatment goals.^[1][12]

Modern medicine offers both standard treatments that have been proven effective through years of research and newer experimental therapies being tested in clinical trials. Medical societies and expert groups have developed guidelines to help doctors choose the most appropriate treatments based on scientific evidence. At the same time, researchers continue to search for better therapies that can help patients live longer with fewer side effects. This ongoing research means that treatment options for metastatic squamous cell lung cancer are constantly evolving, offering new hope to patients diagnosed with this challenging disease.^[10][13]

Standard Treatment Approaches for Metastatic Disease

When squamous cell lung cancer has metastasized, standard treatment typically involves a combination of different therapeutic approaches. The backbone of treatment for most patients includes chemotherapy, which uses drugs to kill rapidly dividing cancer cells throughout the body. For decades, platinum-based chemotherapy doublets have been the foundation of treatment. These regimens combine a platinum drug—either cisplatin or carboplatin—with another chemotherapy medication. The combination works by damaging the DNA of cancer cells in different ways, making it harder for them to survive and multiply.^[10]

However, chemotherapy alone often produces modest results. Classic studies showed that platinum-based chemotherapy doublets achieved response rates of only about 20%, with patients surviving a median of approximately 8 months. These limited outcomes led researchers to search for ways to improve treatment effectiveness.^[10]

A major advance came with the introduction of immunotherapy drugs, which help the body’s own immune system recognize and attack cancer cells. These medications, called immune checkpoint inhibitors, work by blocking proteins that prevent immune cells from attacking cancer. Several immunotherapy drugs have become standard treatment for metastatic squamous cell lung cancer, including pembrolizumab, nivolumab, atezolizumab, and cemiplimab. For patients whose tumor cells show high levels of a protein called PD-L1 (50% or greater), immunotherapy alone may be used as initial treatment. However, for patients with lower PD-L1 levels, combining immunotherapy with chemotherapy has become the preferred approach.^[13]

One commonly used regimen combines cemiplimab with platinum-based chemotherapy. The immunotherapy drug helps activate the immune system while the chemotherapy directly attacks cancer cells, creating a two-pronged assault on the disease. This combination approach has shown better results than chemotherapy alone, helping patients live longer and potentially experiencing tumor shrinkage.^[13]

Another standard option is the CheckMate 9LA regimen, which combines two different immunotherapy drugs—nivolumab and ipilimumab—with a limited course of chemotherapy. Patients receive just two cycles of platinum doublet chemotherapy along with the immunotherapy drugs, followed by maintenance treatment with nivolumab and ipilimumab. This approach was tested in a large phase 3 clinical trial involving over 700 patients and showed improved overall survival compared to chemotherapy alone, with benefits lasting for three years or more in some patients.^[13]

The duration of treatment varies considerably among patients. Some may continue therapy for many months or even years if the cancer remains controlled and side effects are manageable. Others may need to switch to different treatments if the cancer progresses or if side effects become too severe. Doctors typically assess how well treatment is working by performing imaging scans every few months to see whether tumors are shrinking, staying stable, or growing.^[12]

Beyond these systemic treatments that work throughout the body, patients may also receive palliative therapies aimed at relieving specific symptoms. These can include radiation therapy to shrink tumors causing pain or breathing problems, procedures to drain fluid that accumulates around the lungs, or medications to manage pain, shortness of breath, and other symptoms. Palliative care focuses on comfort and quality of life and can be provided alongside active cancer treatment.^[19]

Understanding Side Effects of Standard Treatment

All cancer treatments can cause side effects, though not every patient experiences every possible effect. Chemotherapy typically causes side effects because it attacks rapidly dividing cells throughout the body, not just cancer cells. Common problems include nausea and vomiting, loss of appetite, hair loss, fatigue, increased risk of infections due to low white blood cell counts, anemia causing tiredness and weakness, and easy bruising or bleeding from low platelet counts. Some chemotherapy drugs can also cause nerve damage leading to numbness or tingling in the hands and feet, a condition called peripheral neuropathy.^[1]

Immunotherapy causes a different pattern of side effects. Because these drugs activate the immune system, they can sometimes cause the immune system to attack normal tissues in the body, leading to inflammation. Common immune-related side effects include fatigue, skin rashes and itching, diarrhea or colitis affecting the intestines, inflammation of the liver causing elevated liver enzymes, thyroid problems that can make patients feel tired or anxious, and lung inflammation causing cough or breathing difficulty. More rarely, immunotherapy can affect the nervous system, kidneys, heart, or other organs. Most immune-related side effects can be managed with medications that suppress the immune system, such as corticosteroids, though sometimes immunotherapy needs to be stopped temporarily or permanently.^[13]

Healthcare teams carefully monitor patients during treatment, checking blood counts and organ function regularly. They also ask about symptoms at each visit. Many side effects can be prevented or effectively managed if caught early, so patients should report any new or worsening symptoms promptly rather than waiting for the next scheduled appointment.

Innovative Therapies Being Tested in Clinical Trials

While standard treatments have improved outcomes for many patients with metastatic squamous cell lung cancer, researchers continue to search for even better options. Clinical trials test new drugs and treatment combinations to see if they can help patients live longer, reduce side effects, or offer hope to those whose cancer has stopped responding to standard therapies.

Clinical trials follow a structured process divided into phases. Phase I trials are the first studies in humans and focus primarily on safety—determining what dose can be given safely and what side effects occur. These early trials usually involve small numbers of patients who have already tried standard treatments. Phase II trials enroll more patients and begin to assess whether the new treatment shows signs of working against the cancer. Researchers look for evidence that tumors are shrinking or that patients are living longer. Phase III trials are large comparison studies that test whether the new treatment is better than current standard treatment. These trials may involve hundreds or thousands of patients at many medical centers, sometimes in multiple countries. Only treatments that prove safe and effective in phase III trials typically become new standard treatments approved by regulatory authorities.^[12]

For squamous cell lung cancer specifically, several promising approaches are being explored in clinical trials. One major area of research focuses on finding better ways to use immunotherapy. Scientists are testing combinations of different immunotherapy drugs that work through distinct mechanisms, hoping that attacking cancer through multiple immune pathways will be more effective than single-drug approaches. Other trials are examining whether adding immunotherapy to other treatment types, such as targeted drugs or different chemotherapy combinations, can improve results.^[10]

Another research direction involves targeted therapies designed to attack specific molecular abnormalities in cancer cells. While squamous cell lung cancer has historically had fewer targetable mutations than other lung cancer types like adenocarcinoma, scientists continue to identify new potential targets. Some trials are testing drugs that block specific proteins or signaling pathways that cancer cells depend on for growth and survival. These targeted agents are designed to be more selective than chemotherapy, attacking cancer cells while causing less damage to normal tissues.^[10]

Clinical trials for metastatic squamous cell lung cancer are being conducted at major cancer centers in the United States, Europe, and other regions around the world. Patient eligibility for trials depends on many factors including the stage and extent of disease, previous treatments received, overall health status, and specific characteristics of the tumor. Some trials are specifically designed for patients who have not yet received any treatment for metastatic disease, while others focus on patients whose cancer has progressed after initial therapy.^[12]

When trials show positive results—such as patients living longer, experiencing fewer side effects, or having better quality of life—the findings are published in medical journals and presented at scientific conferences. This allows doctors around the world to learn about new advances. Successful phase III trials often lead to regulatory approval of new treatments, which then become available to patients outside of clinical trials. This is how many of today’s standard treatments, including the immunotherapy drugs now commonly used for squamous cell lung cancer, first proved their value.

Most common treatment methods

• Chemotherapy
  • Platinum-based doublets combining cisplatin or carboplatin with another chemotherapy drug have been the foundation of treatment for decades
  • Works by damaging cancer cell DNA to prevent cell division and growth
  • Usually given in cycles every few weeks, with rest periods between treatments
  • Can cause side effects including nausea, hair loss, fatigue, and increased infection risk
• Immunotherapy
  • Immune checkpoint inhibitors like pembrolizumab, nivolumab, atezolizumab, and cemiplimab help the immune system attack cancer cells
  • May be used alone for patients with high PD-L1 levels or combined with chemotherapy for others
  • Works by blocking proteins that prevent immune cells from attacking cancer
  • Can cause immune-related side effects including rash, diarrhea, liver inflammation, and thyroid problems
• Combination approaches
  • Cemiplimab plus platinum-based chemotherapy combines immune activation with direct cancer cell killing
  • CheckMate 9LA regimen uses two immunotherapy drugs (nivolumab and ipilimumab) with limited chemotherapy
  • Combination treatments showed improved survival compared to chemotherapy alone in clinical trials
  • Requires careful monitoring for side effects from multiple drug types
• Palliative treatments
  • Radiation therapy can shrink tumors causing pain, bleeding, or breathing problems
  • Procedures to drain fluid buildup around the lungs or heart
  • Medications to manage symptoms including pain, shortness of breath, and fatigue
  • Focus on improving quality of life and can be given alongside cancer-directed treatments
• Clinical trial therapies
  • Novel immunotherapy combinations testing different immune checkpoint inhibitors together
  • Targeted drugs designed to block specific proteins or pathways cancer cells need for growth
  • Experimental treatments offered through phase I, II, or III clinical trials at cancer centers
  • May provide access to promising new approaches before they become standard treatment